eszopiclone qHS

Phase 2Small molecule

UUniversity of California, Los Angeles

eszopiclone qHS is one of 76 small molecule programs targeting Insomnia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InsomniaActive, not recruiting

Obstructive Sleep ApneaRecruiting

InsomniaPreclinical

Active, not recruiting

Obstructive Sleep ApneaPhase 2

Recruiting

Competition

Competitive Landscape

52 competitors in Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

5 2

Aldactone

Pfizer

Approved

1 3

Aricept

Eisai

Approved

1 4

Humira

Novartis

Approved

1 5

Singulair

OOrganon and Co

Approved

4 6

Provigil

NNuvo Research GmbH

Approved

4 7

Rozerem

Takeda

Approved

—8

Effexor

WWyeth-Lederle Vaccines

Approved

3 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

3 10

Nuvigil

NNuvo Research GmbH

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Obstructive Sleep Apnea

NCT05953610

Clinical

Trials by Indication[1]

Insomnia1 trial

Testing the Nocturnal Sleep Latency Profile in Primary Insomnia

Completed·UUniversity of Pittsburgh··NCT00167375·24 enrolled

Obstructive Sleep Apnea1 trial

Endotypic Traits and Obstructive Sleep Apnea Surgery

Recruiting·UUniversity of California, Los Angeles·Phase 2·NCT05953610·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for eszopiclone qHS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — eszopiclone qHS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for eszopiclone qHS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of California, Los Angeles

eszopiclone qHS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Insomnia1 trial

Obstructive Sleep Apnea1 trial

References

Drug Info

Quick Facts

Related News